{"groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"FG000","title":"Ixabepilone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible-Wrong primary cancer site"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible- Wrong cell type"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible-Never treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"comment":"Eligible and treated patients","groupId":"FG000","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}